Navigation Links
Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
Date:3/29/2013

k related to the PROCAPS agreement which we terminated in 2012 and decreased litigation costs related to a settlement in 2011.

About Galectin TherapeuticsGalectin Therapeutics (NASDAQ: GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function.  We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development.  We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer.  Additional information is available at www.galectintherapeutics.com.

Forward Looking StatementsThis press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements relate to future events or future financial performance, and use words such as "may," "estimate," "could," "expect" and others.  They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements.  Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others: incurrence of operating losses since our inception, uncertainty as to adequate financing of our operations, extensive and costly regulatory oversight that could restrict or prevent product commercialization, inability to achieve commercial product acceptance, inability to protect our intellectual property, dependence on strategic partnerships, product c
'/>"/>

SOURCE Galectin Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Galectin-3 Assessed as a Biomarker of Heart Failure: Key Clinical Trial Findings Published by Dove Medical Press
2. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
3. Nile Therapeutics Reports 2011 Third Quarter Financial Results
4. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
5. Fate Therapeutics Strengthens Its iPSC Platform
6. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
7. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
8. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
9. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
10. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
11. Aratana Therapeutics Completes $15 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014 /PRNewswire-iReach/ -- DeepResearchReports.com ... China Acetic Acid Industry" and "2014 Deep Research ... reports to its research database. Photo ... Deep Research Report on Global and China Acetic ... report on China and ...
(Date:9/18/2014)... September 18, 2014 ... http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced the addition ... Global Strategic Business Report" report ... ,This report analyzes the worldwide markets ... by the following Product Segments: Polymeric ...
(Date:9/18/2014)... DUBLIN , Sept. 18, 2014 ... the "Global and Chinese Stem Cell Industry Report, ... Stem cells are undifferentiated biological cells that can differentiate ... produce more stem cells. Stem cell therapy can be ... of hematological system disease), nervous system diseases, damage or ...
(Date:9/18/2014)... 2014 Research and Markets has ... (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends ... The global companion diagnostics market is ... 2014 to 2019. Factors such as rising need for ... diagnostics by the pharmaceutical industry, support from regulatory authorities, ...
Breaking Biology Technology:Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 2Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 3Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 4Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3
... 5 , - Exchange: OTCBB, Immureboost Inc. announced ... Inc., Fountain Healthy Aging Inc. said this approval follows ... Directors and the Shareholders,of the Company., CEO, Dr Tony ... a,new direction and a completely new business plan ", ...
... the first to use rapid, automated DNA sequencing to ... perform microbial ,fingerprinting, ... in the,development of state of the art genomic and informational ... Patent,and Trademark Office (USPTO) recently issued U.S. Patent no. 7,449,808, ...
... 5 /Xinhua-PRNewswire-FirstCall/ -- Huifeng Bio-,Pharmaceutical Technology, Inc (OTC ... producer of plant extracts and pharmaceutical raw,materials for ... China, is pleased to announce a Letter of ... Qinba Xintong Medical Ltd. ("Qinba").,Under the proposed terms ...
Cached Biology Technology:Immureboost Inc Announces a Change of Name to Fountain Healthy Aging Inc 2eGenomics Awarded First U.S. Patent Covering Rapid DNA Sequencing Technology Platform to Control Hospital-Acquired Infections 2eGenomics Awarded First U.S. Patent Covering Rapid DNA Sequencing Technology Platform to Control Hospital-Acquired Infections 3Huifeng Bio-Pharmaceutical (HFGB) Enters into Letter of Intent with Xi'an Qinba Xintong Medical Ltd. 2
(Date:9/18/2014)... it that when people are too stressed they are ... the Brain Mind Institute (BMI) at EPFL have just ... between chronic stress and the loss of social skills ... attacks a synaptic regulatory molecule in the brain. This ... Communications . , Carmen Sandi,s team went to ...
(Date:9/18/2014)... lives nestling in the protective tentacles of host anemones, ... travel hundreds of kilometres across the open ocean. Although ... been predicted, this is the first time that the ... been observed. , Dr Steve Simpson, Senior Lecturer in ... Exeter, and colleagues from the Australian Research Council Centre ...
(Date:9/17/2014)... his doctoral student have designed a device based on ... fog and dew., The device could provide water in ... globe., Cheng Luo, professor in the Mechanical & Aerospace ... same College of Engineering department, published "Bioinspired Plate-Based Fog ... Chemical Society) Applied Materials & Interfaces ...
Breaking Biology News(10 mins):How stress tears us apart 2Expedition finds Nemo can travel great distances to connect populations 2Expedition finds Nemo can travel great distances to connect populations 3Shorebird's beak inspires UT Arlington research on water collection 2
... Drugs that target the way cells convert nutrients ... range of conditions including heart attack and stroke. ... a team led by Massachusetts General Hospital (MGH) researchers ... drug, that can shift cellular energy metabolism processes in ...
... proteins found in our intestines can recognize and kill bacteria ... at Emory University School of Medicine have discovered. The ... appear in the journal Nature Medicine . Many ... surfaces of bacteria, but these proteins are different because they ...
... 2010) The wait is over for 16-year-old Francesco "Frank" ... heart in a nine-hour transplant operation at Texas Children,s Heart ... child ever discharged from a pediatric hospital with an implanted ... pediatric patients with VADs remained in the hospital, often in ...
Cached Biology News:Shifting cellular energy metabolism may help treat cardiovascular disease 2Shifting cellular energy metabolism may help treat cardiovascular disease 3Bacteria-killing proteins cover blood type blind spot 2Bacteria-killing proteins cover blood type blind spot 3Texas Children's discharges history-making patient 2
... The StatMatic I provides a convenient and ... culture work. Used with an eight-port disposable ... not possible with multi-channel pipettes. The eight-port ... in volumes of 100, 200, 250, or ...
384 Well PCR Plate Carrier for Thermo-Sealer...
These 18x18 square No.1 Corning cover glasses are made from No. 0211 zinc titania glass and are 0.16 to 0.19mm thick....
... are hydrophobic cover slips for in ... genomic arrays on glass slides., ... Hybri-slips do not adsorb probes. , ... to use. , Avoid RNA degradation-Hybri-slips ...
Biology Products: